A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden. TNBC has an aggressive clinical course and poorer disease-free survival compared to other subtypes. While patients who have no remaining tumor in the breast or lymph nodes after surgery have excellent long-term outcomes, patients with moderate or extensive residual cancer burden remain at high risk for early disease return and poorer prognosis. STEMVAC is designed to targ

Trial Details

NCT ID
NCT07721259
Phase
PHASE2
Sponsor
University of Washington
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
  • Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
  • Biospecimen Collection
Locations (sample)
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • At least 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2
  • Triple-negative breast cancer as determined by the treating oncologist
  • Completed standard of care neoadjuvant chemotherapy in the opinion of their treating oncologist

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →